AstraZeneca Pharma India Limited (IN:ASTRAZEN)
:ASTRAZEN
Want to see IN:ASTRAZEN full AI Analyst Report?
ASTRAZEN Stock Chart & Stats
₹8431.70
₹585.60(8.51%)
At close: 4:00 PM EST
₹8431.70
₹585.60(8.51%)
Day’s Range― - ―
52-Week Range₹7,630.00 - ₹10,653.05
Previous CloseN/A
Volume65.42K
Average Volume (3M)602.00
Market Cap
₹206.22B
Enterprise Value₹212.41B
Total Cash (Recent Filing)₹4.10B
Total Debt (Recent Filing)₹347.90M
Price to Earnings (P/E)109.7
Beta0.74
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.35%
Share Statistics
EPS (TTM)79.66
Shares Outstanding25,000,000
10 Day Avg. Volume682
30 Day Avg. Volume602
Financial Highlights & Ratios
PEG Ratio1.67
Price to Book (P/B)22.24
Price to Sales (P/S)8.53
P/FCF Ratio6.05K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth / Commercial MomentumMeaningful revenue scaling (FY2026 growth 13.6%) indicates expanding market penetration and sustained demand for its branded specialty and chronic therapies. Durable top-line growth supports investment in sales, launches and longer-term market share even amid margin variability.
Conservative Balance SheetA conservatively financed balance sheet with debt-to-equity ~0.13 provides financial flexibility to fund launches, capex, or absorb shocks. Low absolute leverage supports creditworthiness and strategic optionality over the medium term, cushioning operating volatility.
Access To Parent's Global PortfolioAs AstraZeneca's Indian subsidiary, the company benefits from access to patented and specialty medicines, pipeline alignment and brand credibility. Structural access to parent product launches and R&D-backed therapies supports durable revenue and differentiated market positioning.
Bears Say
Margin CompressionGross margin plunged to 26.5% and EBIT margin to 10.3%, suggesting cost pressure or adverse mix. Persistent margin compression would erode EBITDA and free cash flow, constraining reinvestment in high-value specialty launches and reducing long-term profitability resilience.
Weakened Cash GenerationOperating cash flow collapsed to ~68m and free cash flow to ~32m from strong prior-year levels, indicating working-capital swings or higher cash usage. Continued weak cash conversion undermines ability to self-fund growth, dividends and increases dependence on external financing.
Rising Leverage TrendThough leverage remains modest in absolute terms, debt increased materially in FY2026 versus historically near-zero levels. A rising leverage trend combined with weaker cash flow elevates solvency risk and reduces financial flexibility over the medium term if cash generation doesn't recover.
AstraZeneca Pharma India Limited News
ASTRAZEN FAQ
What was AstraZeneca Pharma India Limited’s price range in the past 12 months?
AstraZeneca Pharma India Limited lowest stock price was ₹7630.00 and its highest was ₹10653.05 in the past 12 months.
What is AstraZeneca Pharma India Limited’s market cap?
AstraZeneca Pharma India Limited’s market cap is ₹206.22B.
When is AstraZeneca Pharma India Limited’s upcoming earnings report date?
AstraZeneca Pharma India Limited’s upcoming earnings report date is Aug 17, 2026 which is in 66 days.
How were AstraZeneca Pharma India Limited’s earnings last quarter?
AstraZeneca Pharma India Limited released its earnings results on May 26, 2026. The company reported ₹17.95 earnings per share for the quarter, beating the consensus estimate of N/A by ₹17.95.
Is AstraZeneca Pharma India Limited overvalued?
According to Wall Street analysts AstraZeneca Pharma India Limited’s price is currently Overvalued.
Does AstraZeneca Pharma India Limited pay dividends?
AstraZeneca Pharma India Limited pays a Annually dividend of ₹32 which represents an annual dividend yield of 0.35%. See more information on AstraZeneca Pharma India Limited dividends here
What is AstraZeneca Pharma India Limited’s EPS estimate?
AstraZeneca Pharma India Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AstraZeneca Pharma India Limited have?
AstraZeneca Pharma India Limited has 25,000,000 shares outstanding.
What happened to AstraZeneca Pharma India Limited’s price movement after its last earnings report?
AstraZeneca Pharma India Limited reported an EPS of ₹17.95 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.145%.
Which hedge fund is a major shareholder of AstraZeneca Pharma India Limited?
Currently, no hedge funds are holding shares in IN:ASTRAZEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AstraZeneca Pharma India Limited
AstraZeneca Pharma India Limited operates as a biopharmaceutical entity, engaged in the development, production, and global commercialization of pharmaceutical products, serving both the Indian domestic market and international clientele. The company offers an extensive range of medications, including treatments for cardiovascular conditions and diabetes, marketed under brands such as Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN. Its respiratory portfolio features products like Symbicort and FASENRA, while its oncology division provides various cancer therapies, including LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex. Furthermore, the firm extends its product line to encompass therapeutic solutions for renal, metabolic, and immunological disorders. Beyond its pharmaceutical offerings, AstraZeneca Pharma India Limited also provides clinical trial services. Established in 1979, the company is based in Bengaluru, India, and functions as a subsidiary of AstraZeneca Pharmaceuticals AB.
Technical Analysis
Alkem Laboratories Ltd.
―
GlaxoSmithKline Pharmaceuticals Limited
―
Glenmark Pharmaceuticals Limited
―